Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mullane

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
The New England Journal of Medicine|May 28, 2020
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19Jason D Goldman, David C B Lye, David S Hui, et al.
Open Forum Infectious Diseases|July 20, 2021
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day MortalitySusan A Olender, Theresa L Walunas, Esteban Martinez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2019
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant RecipientsRoy F Chemaly, Sanjeet S Dadwal, Anne Bergeron, et al.
JAMA|August 22, 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical TrialChristoph D Spinner, Robert L Gottlieb, Gerard J Criner, et al.
The Lancet. Infectious Diseases|March 13, 2016
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisFrancisco M Marty, Luis Ostrosky-Zeichner, Oliver A Cornely, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
The New England Journal of Medicine|May 28, 2020
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19Jason D Goldman, David C B Lye, David S Hui, et al.
Open Forum Infectious Diseases|July 20, 2021
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day MortalitySusan A Olender, Theresa L Walunas, Esteban Martinez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2019
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant RecipientsRoy F Chemaly, Sanjeet S Dadwal, Anne Bergeron, et al.
JAMA|August 22, 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical TrialChristoph D Spinner, Robert L Gottlieb, Gerard J Criner, et al.
The Lancet. Infectious Diseases|March 13, 2016
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisFrancisco M Marty, Luis Ostrosky-Zeichner, Oliver A Cornely, et al.
Pageof 12